eFFECTOR Therapeutics, Inc. EFTR
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $200.0K
- P/E
- 0.0×
Follow EFTR
| Older periods | Jun '23 | Sep '23 | Dec '23 | Mar '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(335.14%) | (946.56%) | 3,771.56% | 1,737.63% | |
| (105.73%) | (126.53%) | (144.34%) | (141.18%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,529.48%) | 884.81% | 615.52% | (3,976.00%) | |
Average Days of Receivables |
0.00 | 0.00 | — | — | |
Free Cash Flow per Share |
(16.36) | (12.47) | (13.56) | (7.15) | |
Free Cash Flow |
(31.29) | (30.82) | (29.65) | (29.19) | |
Capital Expenditures |
(0.10) | (0.06) | (0.10) | — | |
Piotroski F-Score |
1.00 | 1.00 | — | — | |
| Other line items | |||||
Cash ROIC |
(66.60%) | (92.89%) | (92.46%) | (64.69%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | — | — | |
Accounts Payable Turnover |
0.08 | 0.09 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | — | — | |
Average Days of Payables |
5,296.15 | 3,839.26 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.84 | 0.86 | 0.83 | 0.84 | |
Depreciation/Fixed assets |
(1.19) | (1.64) | (2.59) | (1.59) | |
Capex/Depreciation |
0.39 | 0.14 | 0.27 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(16.30) | (12.45) | (13.51) | (7.15) | |
Capex per Share |
(0.05) | (0.02) | (0.04) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates